Tessa Therapeutics Pte Ltd
8 Temasek Boulevard
#24-02 Suntec Tower 3
Tel: 65 6384 0755
About Tessa Therapeutics Pte Ltd
Tessa Therapeutics is a clinical stage biopharmaceutical company with the scientific vision of revolutionizing the treatment of cancer by redirecting the body’s potent anti-viral immune response to recognize and kill cancer cells. Tessa’s core virus-specific T cell (VST) platform has shown compelling results in the treatment of solid tumors, and the company is building a portfolio of therapies addressing a wide range of tumors by combining the qualities of its T cell platform with complementary technologies.
CEO: Andrew Khoo
COO: John Ng
CFO: Desmond Lim
35 articles with Tessa Therapeutics Pte Ltd
The collaboration with China-Singapore Guangzhou Knowledge City will focus on the most prevalent cancers in China.
Pharma, biotech and life science companies from across the globe share data and progress on pipelines and other company events.
Tessa Therapeutics, in Collaboration with Baylor College of Medicine, Presents Preclinical Results Showing Enhanced T Cell Responses Against HER2-Positive Solid Tumors Using Novel Combination CAR T Cell Therapy
Preclinical, 'proof-of-concept' results for a novel 'all-in-one' immunotherapy for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-positive solid tumors
Pharma and biotechs from across the globe share news, pipeline updates, with stories from Vetter, Atomwise, Tessa, GenSight, and more.
Tessa Therapeutics Announces Collaboration with Merck Investigating the Combination of KEYTRUDA® (pembrolizumab) and Virus-Specific T Cell Therapy Targeting Human Papillomavirus in Cervical Cancer
The collaboration will evaluate the safety and efficacy of Tessa's armored human papillomavirus-specific T cell (HPVST) therapy combined with Merck's KEYTRUDA® (pembrolizumab) to address the limited number of effective treatment options for metastatic or recurrent cervical cancer
3/8/2019Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family.
Mr. Buchalter brings over thirty years' experience in the biopharmaceutical industry, with strong corporate leadership and an extensive background in the commercial positioning and development of therapeutics in oncology
12/26/2018Companies closed out the year with a number of appointments and hires to strengthen their leadership teams, including changes at the FDA, Melinta, CLSA, Virion, and more.
Distinguished Breast Cancer Expert, Dr. George W. Sledge, Jr., M.D., to join the Board of Tessa Therapeutics
Dr. George W. Sledge, Jr., M.D., is Professor and Chief of Medical Oncology at the Stanford University Medical Center
12/3/2018Biotechs and pharmas strengthened their leadership teams with these appointments. Find news from Mersana, Foamix, Allergan, and more.
Vineti’s software platform for cell therapy workflows will support Tessa’s Asia operations and global capabilities, help scale transformative research in personalized cell therapies for solid tumors, and transition to commercial operations
The collaboration between St. Jude and Tessa aims to advance cellular immunotherapy treatments for childhood cancer
Tessa Therapeutics Announces Opening of Recruitment Sites Across the United States for its Phase III Nasopharyngeal Cancer Immunotherapy Trial
The first T cell infusion under the trial in the U.S. was carried out at City of Hope National Medical Center.
The $80M financing round led by Temasek and joined by EDBI, Karst Peak Capital, Heliconia, Heritas and other investors.
Mr. Lim has over 25 years of finance experience and has held multiple senior executive roles in the recent decade.